"Albumin Hitchhiking" with an Evans Blue Analog for Cancer Theranostics

Although 177Lu-DOTA-TATE was recently approved in Europe for the treatment of certain neuroendocrine tumors, continued development and optimization has been ongoing to further improve the therapeutic efficacy of somatostatin receptor 2 targeted peptide receptor radionuclide therapy, as well as reducing the renal toxicity. In this work, the use of an Evans blue analog for "albumin hitchhiking" resulted in significant improvement in both the imaging performance and therapeutic efficacy of radiolabeled octreotate, as well as reducing the toxicity since much less radioactivity was used for therapy. Upon clinical translation, such "albumin hitchhiking" could make significant impact in the near future for cancer patient management.

Theranostics. 2018 Jan 01*** epublish ***

Emily B Ehlerding, Xiaoli Lan, Weibo Cai

Department of Medical Physics, University of Wisconsin - Madison, Madison, WI 53705., Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe